Spurious and Counterfeit medicines is an increasing concern for the patients, industry, and national policy-makers. It has become one of the key issues besieging the entire world – both the developing as well as the developed nations. The pharmaceutical sector is a strategic sector for India as it contributes to public health, generates positive effects on the Indian economy and improves the general level of welfare. It is crucial to bear in mind from the outset that the “pharmaceutical sector” in the broad sense includes a variety of other actors, ranging from suppliers of medicinal products ingredients (in particular the active pharmaceutical ingredient, “API”), importers, wholesalers (including parallel traders), retailers/pharmacies, and other traders (brokers, etc.). Concerning pharmaceuticals, reduced safety, quality, or efficacy can be life-threatening. In this respect, pharmaceuticals are distinct from many other consumer products.
Even one single case of spurious medicine is not acceptable because, in addition to putting patients at risk and undermining the public confidence in their medicines. The challenge is that wrongful duplication occurs in even low cost pharmaceutical products, many of which could be critical or life saving medicines. This makes it a very serious concern as such products not only harm the nation’s citizens but also potentially percolate across the national borders to the entire world. Such occurrence also results into a very wrong perception of the country it originates and immensely damages the reputation of a nation as the source and hub of spurious / counterfeiting activity. Read More